Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Eli Lilly's stock shows robust momentum and strong analyst support, driven by solid fundamentals and positive market sentiment, while upcoming earnings releases remain a focal point for investors.
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older.
Wall Street, according to CNBC's Mad Money host Jim Cramer, is no longer a monolithic entity but rather a fractured landscape operating under three distinct economic realities. In recent broadcasts around October 8 and 9, 2025, Cramer articulated a vision of the market segmented into a booming Artificial Intelligence and
Investors are eagerly awaiting the start of earnings season for market direction, as the continued government shutdown is creating a lack of economic data
